Hepion Pharmaceuticals Reports Q3 2025 Financial Results with Reduced Losses and Strategic Shift to Diagnostics

Hepion Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $472,506, a significant reduction from the $4,865,948 loss recorded in the same period of 2024. The company did not generate any revenue during the quarter, consistent with its previous performance. Total operating expenses for the quarter were $527,902, down from $4,458,259 in the prior year, primarily due to a decrease in research and development costs, which fell from $2,762,709 to zero, and a reduction in general and administrative expenses from $1,695,550 to $527,902.

For the nine months ending September 30, 2025, Hepion reported a net loss of $7,620,965, compared to a loss of $11,644,966 for the same period in 2024. The decrease in losses was attributed to a significant reduction in total operating expenses, which dropped from $18,144,424 to $3,554,008. This decline was driven by lower research and development expenses, which decreased from $12,438,956 to $445,512, and a new asset impairment loss of $402,746 related to a licensing agreement with New Day Diagnostics.

In terms of strategic developments, Hepion entered into a licensing agreement with New Day Diagnostics in May 2025, acquiring diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and hepatocellular carcinoma. The agreement included an upfront payment of $525,000 and additional milestone payments totaling up to $17.15 million, contingent on achieving specific regulatory and sales targets. This move marks a shift in the company's focus from drug development to diagnostic testing, as it seeks to leverage the CE-marked products eligible for sale in the European Union.

Operationally, Hepion's cash position improved significantly, with cash at the end of September 2025 totaling $2,321,078, up from $406,408 at the end of 2024. The company reported working capital of $3.4 million, a notable increase from a working capital deficit of $1.5 million at the end of the previous year. This improvement was primarily due to net proceeds of $8.2 million from equity issuance, which helped offset operational costs and a $2.9 million payment related to a note payable.

Looking ahead, Hepion faces substantial challenges, including the need for additional capital to continue operations. The company has not generated revenue to date and has incurred significant losses since its inception. Management has expressed concerns about its ability to continue as a going concern without securing further financing. The company is actively exploring options to raise additional funds, which may involve issuing equity securities, potentially leading to dilution for existing shareholders.